SI
NGEN

Sprott Inc’s NervGen Pharma NGEN Stock Holding History

Sprott Inc’s Portfolio NGEN Stock Details NGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.5K Hold
25,000
– – ﹤0.01% 259
2026
Q1 		$94.3K Buy
+25,000
New +$108K ﹤0.01% 228

Other funds holding NGEN

EAM
Empery Asset Management New York $86.5M AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $5.1B AUM 39.13% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Sprott Inc's NGEN Position: Q2 2026 in Review

Sprott Inc held its NervGen Pharma (NGEN) position steady in Q2 2026 at 25,000 shares worth $51.5K. The position accounts for ﹤0.01% of the portfolio, ranked #259.

Sprott Inc first reported a position in NGEN in Q1 2026 and has held it in 2 quarters since. The position peaked at $94.3K in Q1 2026. 62 funds tracked by Wall St. Rank hold NGEN as of Q2 2026.

  • Sprott Inc held 25,000 shares of NervGen Pharma worth $51.5K as of Q2 2026.
  • Sprott Inc left its NervGen Pharma share count unchanged in Q2 2026.
  • NervGen Pharma made up ﹤0.01% of Sprott Inc's portfolio in Q2 2026, its #259 holding.
  • Sprott Inc first reported a position in NervGen Pharma in Q1 2026 and has held it in 2 quarters since.
  • Sprott Inc's NervGen Pharma position peaked at $94.3K in Q1 2026.
  • 62 funds tracked by Wall St. Rank held NervGen Pharma as of Q2 2026.

Based on Sprott Inc's 13F filing for Q2 2026, filed 28 Jul 2026.